In April 2011, the US Food and Drug Administration (FDA) approved florbetapir (trade name Amyvid), the first drug for the imaging of beta-amyloid plaque in the brain. Beta-amyloid plaques in the brain are the hallmark of Alzheimer’s disease (AD). Previously, making a definitive diagnosis of Alzheimer’s disease required post-mortem autopsy of the brain to evaluate for amyloid plaque using a special stain and a microscope. With florbetapir, the presence of amyloid plaque can now be detected non-invasively in live patients during a positron emission tomography/computed tomography (CT/PET) scan.

Florbetapir is labeled with radioactivity and when injected intravenously, the florbetapir binds to amyloid in the brain and the radioactive label allows localization. The radioactivity decreases by half every 2 hours. Given this rapid decay, no special radiation precautions are required. The typical PET/CT scan with florbetapir delivers approximately the same amount of radiation as 3 years of background radiation.

After florbetapir is injected, it is allowed to circulate for 30 minutes. The patient then lies down in a PET/CT scanner (Figure 1). A CT scan of the head is performed in a few seconds and is followed by a ten-minute PET scan. The radiologist then views the three-dimensional image of the brain as slices. Normal scans will show accumulation of radiolabelled florbetapir only in the white matter (Figure 2), while abnormal scans with significant amounts of amyloid plaque will show radioactivity in the white and gray matter out to the periphery of the brain (Figure 3). Although the popular press often displays images of florbetapir scans in color, in routine practice radiologists evaluate the scans in black-and-white.

Although approved by the FDA, florbetapir imaging for AD is not currently covered by Medicare. Most other health plans also do not provide coverage for the scans.

One reason for the lack of coverage is concern about the costs (about $3,000 per scan) that will be generated by extensive use of this imaging to diagnose AD when no therapy is approved to slow or stop the disease after it has been diagnosed.

Concern has also been expressed that a positive florbetapir scan does not by itself provide a definitive diagnosis of AD. For example, some cognitively normal older adults will have a positive scan, even though they do not have and may never develop AD. Patients who have Lewy body dementia (LBD) may also have a positive scan when amyloid is present in the brain, even though AD is not the primary cause of the patient’s dementia. In such cases, a dopamine transporter (DaT) scan can help sort out the basis for the patient’s cognitive dysfunction.

Conversely, a negative scan means that a patient has little or no amyloid plaque at the time of the scan. But, it does not mean that the patient will never develop amyloid plaque in the future.

**TIPS FOR USE OF AMYLOID IMAGING FOR DIAGNOSIS ALZHEIMER’S DISEASE**

- Keep in mind that currently, Medicare and most health insurance plans will not pay for amyloid scans. So, only order them if they will change the plan of care.
- A patient with a typical presentation of Alzheimer’s disease (AD) does not usually require amyloid imaging for confirmation of the diagnosis.
- Consider ordering an amyloid scan if it would be useful to identify the presence of amyloid, and thus confirm or exclude a diagnosis of AD in patients who present with Alzheimer’s-like dementia at a younger-than-expected age, in patients with mild cognitive impairment who do not meet criteria for AD, and in those with an unclear diagnosis.
Still, there are several clinical situations in which florbetapir scans have potential utility. One is when a patient exhibits findings of AD at a younger-than-expected age (such as a patient with a presenilin-1 mutation). A second is to determine if a patient with mild cognitive impairment who does not meet criteria for AD is simply demonstrating normal age-related memory changes or if the patient is in the early stages of AD. The third is when a patient’s presentation has a differential diagnosis that includes conditions such as frontotemporal dementia, primary progressive aphasia, or posterior cortical atrophy/visual-variant Alzheimer’s syndrome, and the correct diagnosis is unclear. In all of these situations, the presence of significant amyloid on PET/CT would suggest that amyloid pathology is causing the patient’s cognitive impairment, regardless of the clinical presentation.

The other potential use of florbetapir scans is for research on new AD treatments. To determine the efficacy of such treatments, it will be essential to confirm that research subjects do, in fact, have AD. Detection of amyloid with a florbetapir scan will provide that confirmation. Similarly, when studying therapies designed to target amyloid plaque with the intention of slowing the progression of AD, serial florbetapir scans will permit longitudinal assessment of therapeutic outcome.

References and Resources